Drucker Wealth 3.0 LLC Sells 578 Shares of Novartis AG (NYSE:NVS)

Drucker Wealth 3.0 LLC lessened its stake in shares of Novartis AG (NYSE:NVS) by 6.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,425 shares of the company’s stock after selling 578 shares during the period. Drucker Wealth 3.0 LLC’s holdings in Novartis were worth $820,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its position in Novartis by 1.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 8,183,855 shares of the company’s stock valued at $796,372,000 after buying an additional 90,823 shares in the last quarter. Renaissance Technologies LLC increased its position in Novartis by 16.0% during the 4th quarter. Renaissance Technologies LLC now owns 2,668,849 shares of the company’s stock valued at $259,706,000 after buying an additional 368,171 shares in the last quarter. Northern Trust Corp increased its position in Novartis by 23.1% during the 4th quarter. Northern Trust Corp now owns 2,132,591 shares of the company’s stock valued at $207,522,000 after buying an additional 399,862 shares in the last quarter. Fisher Asset Management LLC increased its position in Novartis by 17.4% during the 4th quarter. Fisher Asset Management LLC now owns 2,002,959 shares of the company’s stock valued at $194,908,000 after buying an additional 296,950 shares in the last quarter. Finally, Chevy Chase Trust Holdings LLC increased its position in Novartis by 4.7% during the 4th quarter. Chevy Chase Trust Holdings LLC now owns 1,161,139 shares of the company’s stock valued at $112,990,000 after buying an additional 52,044 shares in the last quarter. Institutional investors own 13.12% of the company’s stock.

Wall Street Analysts Forecast Growth

NVS has been the subject of a number of research analyst reports. Wall Street Zen raised Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 8th. BNP Paribas raised Novartis to a “strong-buy” rating in a report on Tuesday, April 15th. UBS Group reissued a “neutral” rating on shares of Novartis in a report on Thursday, February 13th. Morgan Stanley initiated coverage on Novartis in a report on Wednesday, February 12th. They issued an “underweight” rating for the company. Finally, Deutsche Bank Aktiengesellschaft raised Novartis from a “hold” rating to a “buy” rating in a report on Tuesday, February 4th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $123.38.

Novartis Stock Performance

NVS stock opened at $112.77 on Friday. The company has a market cap of $238.21 billion, a P/E ratio of 19.18, a price-to-earnings-growth ratio of 1.70 and a beta of 0.60. Novartis AG has a 1 year low of $96.06 and a 1 year high of $120.92. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. The stock’s fifty day moving average price is $109.87 and its 200-day moving average price is $105.85.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, April 29th. The company reported $2.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.12 by $0.16. The firm had revenue of $13.23 billion for the quarter, compared to the consensus estimate of $12.92 billion. Novartis had a return on equity of 37.24% and a net margin of 23.56%. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period last year, the business posted $1.80 EPS. On average, equities analysts forecast that Novartis AG will post 8.45 earnings per share for the current year.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.